Aurora Biomed has signed an agreement with Alion Pharmaceuticals and Specs to form an Ion Channel Consortium to provide a comprehensive solution for ion channel drug discovery
The three companies aim to offer value added identification and validation of ion channel modulators as part of their work within the consortium.
They hope that this research will give scientists the ability to save time and costs while providing a unique method to identify new drug candidates for channelopathies.
Currently, Aurora Biomed provides contract research services for ion channels, channel forming proteins and toxins, creation and testing of mutant cDNA ion channels, and various ion channel cell lines.
